Inactivation of androgens by UDP-glucuronosyltransferases in the human prostate

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 22, Issue 2, 2008, Pages 259-270

  Barbier, Olivier ^a   Bélanger, Alain ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

adrenal androgen glucuronidation; androgens; dihydrotestosterone; prostate; UDP glucuronosyltransferase

Indexed keywords

3ALPHA HYDROXYSTEROID DEHYDROGENASE; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANEDIOL; ANDROSTANOLONE; ANDROSTERONE; ANTINEOPLASTIC AGENT; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 2A; GLUCURONOSYLTRANSFERASE 2B; GLUCURONOSYLTRANSFERASE 2B15; GLUCURONOSYLTRANSFERASE 2B17; GLUCURONOSYLTRANSFERASE 2B7; KALLIKREIN; MONOCARBOXYLATE TRANSPORTER; PROSTATE SPECIFIC ANTIGEN; SMALL INTERFERING RNA; TESTOSTERONE 17BETA DEHYDROGENASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NKX3.1; TRANSFERASE; VASCULOTROPIN;

ANDROGEN METABOLISM; BINDING AFFINITY; CANCER RISK; DNA POLYMORPHISM; DRUG RESEARCH; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME LOCALIZATION; ENZYME SUBSTRATE; GENE DELETION; GLUCURONIDATION; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FAMILY; RECEPTOR BINDING; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TISSUE DISTRIBUTION;

ANDROGEN ANTAGONISTS; ANDROGENS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; HYDROXYSTEROID DEHYDROGENASES; MALE; METABOLIC DETOXICATION, PHASE I; METABOLIC DETOXICATION, PHASE II; MODELS, BIOLOGICAL; POLYMORPHISM, GENETIC; PROSTATE;

EID: 42949113073     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2008.01.001     Document Type: Review

References (40)

1. Hunter J. Observations on certain parts of the animal oeconomy. 1786;37.
2. White J.W. I. The results of double castration in hypertrophy of the prostate. Annals of Surgery 22 1 (1895) 1-80
3. Ruzicka L. The artificial preparation of the male sex hormone. Current Science 80 (2001)
4. Huggins C. Endocrine control of prostatic cancer. Science 97 2529 (1943) 541-544
5. Perez C.A., Fair W.R., Ihde D.C., et al. Cancer of the prostate. Cancer, principles and practice of oncology (1985), Lippincott, Philadelphia 929-964
6. Labrie F., Dupont A., Bélanger A., et al. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clinical and Investigative Medicine 5 (1982) 267-275
7. Bruchovsky N., and Wilson J.D. The intranuclear binding of testosterone and 5-alpha-androstan-17-beta-ol-3-one by rat prostate. The Journal of Biological Chemistry 243 22 (1968) 5953-5960
8. Labrie F., Luu-The V., Belanger A., et al. Is dehydroepiandrosterone a hormone?. The Journal of Endocrinolology 187 2 (2005) 169-196
9. In: Dutton G.J. (Ed). Glucuronidation of drugs and other compounds (1980), CRC Press, Boca Raton, FL
10. Mackenzie P.I., Owens I.S., Burchell B., et al. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 7 4 (1997) 255-269
11. Tukey R.H., and Strassburg C.P. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annual Review of Pharmacology and Toxicology 40 (2000) 581-616
12. Guillemette C., Belanger A., and Lepine J. Metabolic inactivation of estrogens in breast tissue by UDP-glucuronosyltransferase enzymes: an overview. Breast Cancer Research 6 6 (2004) 246-254
13. Belanger A., Pelletier G., Labrie F., et al. Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans. Trends in Endocrinology and Metabolism 14 10 (2003) 473-479
14. Turgeon D., Carrier J.S., Levesque E., et al. Isolation and characterization of the human UGT2B15 gene, localized within a cluster of UGT2B genes and pseudogenes on chromosome 4. Journal of Molecular Biology 295 3 (2000) 489-504
15. Turgeon D., Carrier J.S., Levesque E., et al. Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 142 2 (2001) 778-787
16. Chouinard S., Pelletier G., Belanger A., et al. Cellular specific expression of the androgen-conjugating enzymes UGT2B15 and UGT2B17 in the human prostate epithelium. Endocrine Research 30 4 (2004) 717-725
17. Belanger A., Candas B., Dupont A., et al. Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. The Journal of Clinical Endocrinology and Metabolism 79 4 (1994) 1086-1090
18. Vermeulen A., and Giagulli V.A. Physiopathology of plasma androstanediol-glucuronide. The Journal of Steroid Biochemistry and Molecular Biology 39 5B (1991) 829-833
19. Belanger A., Brochu M., Lacoste D., et al. Steroid glucuronides: human circulatory levels and formation by LNCaP cells. The Journal of Steroid Biochemistry and Molecular Biology 40 4-6 (1991) 593-598
20. Pang S., MacGillivray M., Wang M., et al. 3 alpha-androstanediol glucuronide in virilizing congenital adrenal hyperplasia: a useful serum metabolic marker of integrated adrenal androgen secretion. The Journal of Clinical Endocrinology and Metabolism 73 1 (1991) 166-174
21. Vexiau P., Fiet J., Boudou P., et al. Increase in plasma 5 alpha-androstane-3 alpha,17 beta-diol glucuronide as a marker of peripheral androgen action in hirsutism: a side-effect induced by cyclosporine A. Journal of Steroid Biochemistry 35 1 (1990) 133-137
22. Moghissi E., Ablan F., and Horton R. Origin of plasma androstanediol glucuronide in men. Journal of Clinical Endocrinology & Metabolism 59 (1984) 417-421
23. Labrie F., Belanger A., Belanger P., et al. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. The Journal of Steroid Biochemistry and Molecular Biology 99 4-5 (2006) 182-188
24. Vandenput L., Labrie F., Mellstrom D., et al. Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. Journal of Bone and Mineral Research 22 2 (2007) 220-227
25. Barbier O., Lapointe H., El Alfy M., et al. Cellular localization of uridine diphosphoglucuronosyltransferase 2B enzymes in the human prostate by in situ hybridization and immunohistochemistry. The Journal of Clinical Endocrinology and Metabolism 85 12 (2000) 4819-4826
26. Hum D.W., Belanger A., Levesque E., et al. Characterization of UDP-glucuronosyltransferases active on steroid hormones. The Journal of Steroid Biochemistry and Molecular Biology 69 1-6 (1999) 413-423
27. Chouinard S., Pelletier G., Belanger A., et al. Isoform-specific regulation of uridine diphosphate-glucuronosyltransferase 2B enzymes in the human prostate: differential consequences for androgen and bioactive lipid inactivation. Endocrinology 147 11 (2006) 5431-5442
28. Guillemette C., Hum D.W., and Belanger A. Evidence for a role of glucuronosyltransferase in the regulation of androgen action in the human prostatic cancer cell line LNCaP. The Journal of Steroid Biochemistry and Molecular Biology 57 3-4 (1996) 225-231
29. Chouinard S., Barbier O., and Belanger A. UDP-glucuronosyltransferase (UGT)2B15 and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells. The Journal of Biological Chemistry 282 46 (2007) 33466-33474
30. Chen F., Ritter J.K., Wang M.G., et al. Characterization of a cloned human dihydrotestosterone/androstanediol UDP-glucuronosyltransferase and its comparison to other steroid isoforms. Biochemistry 32 40 (1993) 10648-10657
31. Levesque E., Beaulieu M., Green M.D., et al. Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics 7 4 (1997) 317-325
32. MacLeod S.L., Nowell S., Plaxco J., et al. An allele-specific polymerase chain reaction method for the determination of the D85Y polymorphism in the human UDP-glucuronosyltransferase 2B15 gene in a case-control study of prostate cancer. Annals of Surgical Oncology 7 10 (2000) 777-782
33. Hajdinjak T., and Zagradisnik B. Prostate cancer and polymorphism D85Y in gene for dihydrotestosterone degrading enzyme UGT2B15: Frequency of DD homozygotes increases with Gleason Score. Prostate 59 4 (2004) 436-439
34. Park J., Chen L., Shade K., et al. Asp85tyr polymorphism in the udp-glucuronosyltransferase (UGT) 2B15 gene and the risk of prostate cancer. The Journal of Urology 171 6 Pt 1 (2004) 2484-2488
35. Okugi H., Nakazato H., Matsui H., et al. Association of the polymorphisms of genes involved in androgen metabolism and signaling pathways with familial prostate cancer risk in a Japanese population. Cancer Detection and Prevention 30 3 (2006) 262-268
36. Jakobsson J., Ekstrom L., Inotsume N., et al. Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. The Journal of Clinical Endocrinology and Metabolism 91 2 (2006) 687-693
37. Swanson C., Mellstrom D., Lorentzon M., et al. The UDP Glucuronosyltransferase 2B15 D85Y and 2B17 Deletion Polymorphisms Predict the Glucuronidation Pattern of Androgens and Fat Mass in Men. The Journal of Clinical Endocrinology and Metabolism 92 12 (2007) 4878-4882
38. Park J.Y., Tanner J.P., Sellers T.A., et al. Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk. Urology 70 2 (2007) 374-379
39. Karypidis A.H., Olsson M., Andersson S.O., et al. Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate. The Pharmacogenomics Journal (2007 Mar 27) (Epub ahead of print)
40. Gallagher C.J., Kadlubar F.F., Muscat J.E., et al. The UGT2B17 gene deletion polymorphism and risk of prostate cancer A case-control study in Caucasians. Cancer Detection and Prevention 31 4 (2007) 310-315